Monte Rosa Therapeutics to Present at 4th Annual Targeted Protein Degradation Summit
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) announced that Sharon Townson, Ph.D., Chief Technology Officer, will present at the virtual 4th Annual Targeted Protein Degradation Summit on October 27 at 11:45 a.m. ET. The presentation, titled “Molecular Glue Degraders: From Serendipity to Rational Design,” will highlight the QuEEN™ platform's role in expanding target space.
Monte Rosa focuses on developing molecular glue precision medicines to selectively eliminate therapeutic proteins using a proprietary protein degradation platform.
- None.
- None.
BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that Sharon Townson, Ph.D., Chief Technology Officer, will present at the virtual 4th Annual Targeted Protein Degradation Summit on Wednesday, Oct. 27 at 11:45 a.m. ET. The presentation, titled, “Molecular Glue Degraders: From Serendipity to Rational Design,” will showcase the capabilities of Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) platform and its impact on expanding target space.
The presentation will be archived under the “Events & Presentations” section of the Company’s investors section of the website at https://ir.monterosatx.com/.
About Monte Rosa
Monte Rosa Therapeutics is a biotechnology company developing a portfolio of novel molecular glue degrader precision medicines. These medicines are designed to employ the body’s natural mechanisms to selectively eliminate therapeutically relevant proteins. The company has developed a proprietary protein degradation platform, called QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates), that enables it to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates that are designed to eliminate therapeutically relevant proteins in a highly selective manner. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, AI/machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine and is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland.
Contacts:
Investors
Michael Morabito, Solebury Trout
ir@monterosatx.com
Media
Dan Budwick, 1AB
dan@1abmedia.com
FAQ
When is the presentation by Sharon Townson of Monte Rosa Therapeutics at the Targeted Protein Degradation Summit?
What is the topic of Sharon Townson's presentation at the summit?
What does Monte Rosa Therapeutics focus on developing?
What is the QuEEN™ platform used for by Monte Rosa Therapeutics?
Where can I find the archived presentation from Monte Rosa Therapeutics?
